Another one of those Pharma companies which was in the wars over the past 1 year..the management has made many mis-steps and lost focus..leading to losses.
All the attention shifted to its biologic business.
THe RSI now had a divergence and the follow thru days show that there could be a bottoming out here.
The stoploss here is 290 and its deep..but this is a high risk high returns kind of play.
Long above 333 (Trendline breakout) and double over 370. (200EMA crossover)
All the attention shifted to its biologic business.
THe RSI now had a divergence and the follow thru days show that there could be a bottoming out here.
The stoploss here is 290 and its deep..but this is a high risk high returns kind of play.
Long above 333 (Trendline breakout) and double over 370. (200EMA crossover)